Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hyperlipidemias Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Hyperlipidemias. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Hyperlipidemias clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Early Phase 1: 1.

Research is led by Capital Medical University (1), Shandong Suncadia Medicine Co., Ltd. (1), Esperion Therapeutics, Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Integrated diagnosis and treatment for CKD (other, 1 trial), followed by HRS-1301 Tablets, Atorvastatin Calcium Tablets.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Hyperlipidemias trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05242055

Integrated Diagnosis and Treatment of CKD on Outcomes

Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to...

Sponsor: Capital Medical UniversityEnrolling: 10001 location
RECRUITINGPhase 1NCT07608705

A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants

This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to...

Sponsor: Shandong Suncadia Medicine Co., Ltd.Enrolling: 161 location
RECRUITINGNCT05103254

Bempedoic Acid Pregnancy Surveillance Program

Bempedoic acid pregnancy surveillance program

Sponsor: Esperion Therapeutics, Inc.Enrolling: 201 location
RECRUITINGNCT06055036

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body...

Sponsor: Ohio State UniversityEnrolling: 3401 location
RECRUITINGNCT05015348

Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia

Patients with hyperlipidemia will be allocated into intervention or control group randomly. Participants of intervention group will be provided with Omega-3 PUFA, while...

Sponsor: Peking Union Medical College HospitalEnrolling: 1201 location
RECRUITINGNCT05703386

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter...

Sponsor: Johns Hopkins UniversityEnrolling: 501 location
RECRUITINGNCT06062394

Penn Medicine Healthy Heart

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that...

Sponsor: University of PennsylvaniaEnrolling: 19801 location
RECRUITINGEarly Phase 1NCT05802121

Akkermansia Muciniphilia and Metabolic Side Effects of ADT

The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool...

Sponsor: Western UniversityEnrolling: 301 location
RECRUITINGNCT05737355

Effect of ANKASCIN 568-P Products Regulating Blood Lipid

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation...

Sponsor: SunWay Biotech Co., LTD.Enrolling: 801 location
RECRUITINGNCT06373913

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased...

Sponsor: Kolding SygehusEnrolling: 751 location

Frequently Asked Questions

There are currently 10 clinical trials for Hyperlipidemias, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hyperlipidemias, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Hyperlipidemias, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.